Kaplan-Meier estimated 3-year survival rates from start of sildenafil were 94 % , 93 % , and 88 % for patients randomized to low - , medium - , and high-dose sildenafil , respectively ; 87 % , 89 % , and 80 % were known to be alive at 3 years .